1. Home
  2. SERV vs CDNA Comparison

SERV vs CDNA Comparison

Compare SERV & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Serve Robotics Inc.

SERV

Serve Robotics Inc.

HOLD

Current Price

$9.20

Market Cap

913.2M

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$17.01

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SERV
CDNA
Founded
2017
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
913.2M
1.0B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
SERV
CDNA
Price
$9.20
$17.01
Analyst Decision
Buy
Buy
Analyst Count
6
7
Target Price
$18.80
$27.33
AVG Volume (30 Days)
3.1M
539.5K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$48,324,000.00
Revenue This Year
$872.80
$15.37
Revenue Next Year
$199.55
$11.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
18.93
52 Week Low
$4.66
$10.96
52 Week High
$18.64
$21.49

Technical Indicators

Market Signals
Indicator
SERV
CDNA
Relative Strength Index (RSI) 41.94 37.34
Support Level $8.02 $16.74
Resistance Level $11.00 $17.09
Average True Range (ATR) 0.67 0.83
MACD 0.06 -0.21
Stochastic Oscillator 6.96 23.77

Price Performance

Historical Comparison
SERV
CDNA

About SERV Serve Robotics Inc.

Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: